New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
07:24 EDTBIODBiodel BIOD-531 demonstrates superior glucose control after meals
Biodel announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog Mix 75/25 and Humulin R U-500 in patients with type 2 diabetes with moderate insulin resistance who use between 50 and 200 units of insulin per day. BIOD-531 was associated with superior glucose control compared to Humalog Mix 75/25 throughout the day of observation. BIOD-531 was also associated with superior glucose control compared to Humulin R U-500. BIOD-531 dosed 20 minutes after the start of the standardized breakfast also resulted in superior glucose control compared to either Humalog Mix 75/25 or Humulin R U-500 dosed prior to the meal. Mean visual analog scores and absolute severity scores were low for all participants, suggesting excellent injection site tolerability.
News For BIOD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
07:32 EDTBIODBiodel 32.69M share Secondary priced at 92c
Subscribe for More Information
April 6, 2015
07:14 EDTBIODBiodel GEM device demonstrates 'superior' usability
Biodel (BIOD) announced results from a formative human factors study of its Glucagon Emergency Management, or GEM, device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. In the study, the GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon kits; Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit. Furthermore, while training and previous experience increased the success rate with the Eli Lilly and Novo Nordisk glucagon kits, it did not further impact the already high success rate with the GEM device when compared to non-experienced, untrained participants.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use